Hims & Hers Health (NYSE:HIMS) Now Covered by Analysts at BTIG Research

BTIG Research initiated coverage on shares of Hims & Hers Health (NYSE:HIMS - Free Report) in a research note released on Tuesday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $35.00 price target on the stock.

HIMS has been the topic of a number of other reports. Deutsche Bank Aktiengesellschaft raised their price target on Hims & Hers Health from $23.00 to $27.00 and gave the company a "hold" rating in a report on Wednesday, November 6th. Bank of America downgraded shares of Hims & Hers Health from a "buy" rating to an "underperform" rating and dropped their price target for the stock from $32.00 to $18.00 in a research report on Thursday, November 14th. Morgan Stanley assumed coverage on shares of Hims & Hers Health in a report on Tuesday, December 17th. They issued an "overweight" rating and a $42.00 price objective for the company. Piper Sandler boosted their target price on Hims & Hers Health from $21.00 to $24.00 and gave the stock a "neutral" rating in a report on Monday. Finally, Needham & Company LLC increased their price target on Hims & Hers Health from $28.00 to $31.00 and gave the company a "buy" rating in a research note on Monday. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $24.80.

Hims & Hers Health Price Performance

Shares of HIMS stock traded up $0.71 during trading hours on Tuesday, reaching $27.61. The stock had a trading volume of 10,914,906 shares, compared to its average volume of 9,194,688. The firm has a 50-day simple moving average of $26.84 and a 200-day simple moving average of $21.57. The firm has a market capitalization of $6.03 billion, a PE ratio of 62.75 and a beta of 1.31. Hims & Hers Health has a twelve month low of $8.14 and a twelve month high of $35.02.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating analysts' consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $401.56 million for the quarter, compared to analysts' expectations of $382.20 million. During the same quarter in the previous year, the company posted ($0.04) earnings per share. The business's revenue for the quarter was up 77.1% compared to the same quarter last year. On average, equities analysts anticipate that Hims & Hers Health will post 0.29 earnings per share for the current year.

Insider Activity at Hims & Hers Health

In other news, insider Soleil Boughton sold 2,339 shares of the company's stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $20.41, for a total value of $47,738.99. Following the transaction, the insider now directly owns 172,274 shares of the company's stock, valued at approximately $3,516,112.34. This represents a 1.34 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $20.88, for a total value of $3,943,981.44. Following the sale, the chief executive officer now directly owns 67,015 shares of the company's stock, valued at approximately $1,399,273.20. The trade was a 73.81 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,333,446 shares of company stock worth $34,175,197. 17.71% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC increased its holdings in Hims & Hers Health by 2,173.7% in the fourth quarter. GAMMA Investing LLC now owns 2,251 shares of the company's stock worth $54,000 after buying an additional 2,152 shares during the last quarter. Quest Partners LLC raised its holdings in shares of Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company's stock valued at $72,000 after purchasing an additional 3,507 shares in the last quarter. CWM LLC lifted its stake in shares of Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company's stock valued at $110,000 after purchasing an additional 1,054 shares during the last quarter. Van ECK Associates Corp bought a new stake in Hims & Hers Health in the second quarter worth $111,000. Finally, Quarry LP increased its position in Hims & Hers Health by 91.0% during the third quarter. Quarry LP now owns 6,113 shares of the company's stock worth $113,000 after buying an additional 2,913 shares during the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.